Table 2.
Oncologic outcomes following TORS for OPSCC.
| Study | Number of cases | Primary site | Pathological stage | HPV status | Followup period (mean) | Oncologic outcomes |
|---|---|---|---|---|---|---|
| Cohen et al. [13] (Apr '10) | 50 | Oropharynx | T1/2: 39 | HPV-neg: 13 | HPV-neg: 23.0 mths | 1 yr: 95.7% (45/47) |
| T3: 11 | 2 yr: 80.6% (25/31) | |||||
| HPV-pos: 37 | HPV-pos: 24.8 mths | |||||
| N0: 9 | ||||||
| N1: 21 | ||||||
| N2a: 0 | ||||||
| N2b: 20 | ||||||
| N2c: 0 | ||||||
| N3: 0 | ||||||
|
| ||||||
| Genden et al. [20] (Aug '11) | 30 | 27 oropharynx (90%) | T1/2: 30/30 | N/A | 20.4 mths | 18 mth: |
| 1 larynx (3.3%) | locoregional control: 91% | |||||
| 1 oral cavity (3.3%) | N0: 6 | distant control: 93% | ||||
| 1 hypopharynx (3.3%) | N1: 10 | DFS: 78% | ||||
| N2a: 5 | OS: 90% | |||||
| N2b: 7 | ||||||
| N2c: 2 | ||||||
| N3: 0 | ||||||
|
| ||||||
| Weinstein et al. [28] (Nov '10) | 47 | Oropharynx | T1/2: 36 | N/A | 26 mths | Overall: |
| T3/4: 11 | 1 yr: 96% (45/47) | |||||
| 2 yr: 82% (27/33) | ||||||
| N0: 1 | DFS: | |||||
| N1: 24 | 1 yr: 96% (45/47) | |||||
| N2a: 1 | 2 yr: 79% (26/33) | |||||
| N2b: 19 | ||||||
| N2c: 2 | ||||||
| N3: 0 | ||||||
|
| ||||||
| White et al. [29] (Dec '10) | 89 | 77 oropharynx (87%) | T1/2: 71 | N/A | 26 mths (median) | DFS (entire cohort) |
| 10 larynx (11%) | T3/4: 18 | 2 years: 86.3% | ||||
| 2 oral cavity (2%) | ||||||
| N0: 27 | DFS (primary TORS cohort) | |||||
| N1: 8 | 2 years: 89.3% | |||||
| N2a: 11 | ||||||
| N2b: 26 | ||||||
| N2c: 12 | ||||||
| N3: 4 | ||||||